PureTech's Gelesis scraps plans for a $60M IPO

A flood of IPOs can't raise every biotech boat. Gelesis has scrapped its plans for a $60 million IPO after evidently failing to find a big enough appetite for its stomach-filling particle approach to combating obesity. The biotech, part of PureTech's portfolio, is shooting to wrap a pivotal study in Europe but noted in its S-1 that it could take four more years to prep for a U.S. approval. The biotech--which raised a $22 million crossover round a couple of months ago--had a problem with its most recent study, which was completed last summer. The study tested Gelesis100 at a 2.25 g dose, a 3.75 g dose and a placebo. That low dose scored a placebo-adjusted weight loss of only 2% of body weight (6.1% total), while the high dose registered a minimal 0.4% placebo-adjusted improvement on the scales. Story

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.